The role of genetics and sex hormones in cases of Melasma in Females of Reproductive age group-A Case-control study
Not Applicable
- Conditions
- Health Condition 1: L811- Chloasma
- Registration Number
- CTRI/2021/04/032603
- Lead Sponsor
- IADVL Academy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Case- Adult women in the reproductive age group suffering from Melasma attending the dermatology outpatient department.
Control- Age-matched otherwise healthy women of reproductive age group without Melasma attending the dermatology outpatient department.
Exclusion Criteria
1. Pregnant, lactating and post-menopausal women
2. Women with the irregular menstrual cycle, polycystic ovary disease and a history of
endocrinopathies.
3. Women on oral contraceptive pills, intrauterine device and hormone replacement therapy
4. Facial dermatitis
5. Albinos
6. History of intake of drugs known to exacerbate Melasma
7. Patients with allergic diseases or bone diseases
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method After completing the patients based on this study and its further validation will be done on cell lines and animal model-based study. Further, MITF expression and Hormonal status if able to provide any significant correlation then more precise therapeutic interventions could be planned, so it may help in providing better management to women suffering from Melasma.Timepoint: 2 years.
- Secondary Outcome Measures
Name Time Method The current study on reproductive hormones with MITF may open new vistas in the understanding of the Melasma disease along-with corresponding drug targets so that better management could be achieved.Timepoint: 2 years.